Pfizer Offers Warranty Payment Approach For New Hemophilia Gene Therapy

Pfizer plans to allow payers to use a “warranty” approach to pay for its new costly gene therapy, the company announced after gaining FDA approval Friday (April 26) of Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adult patients with moderate to severe hemophilia B. In a statement Friday , Pfizer announced it will be “launching an innovative warranty program based on durability of patient response to treatment.” The wholesale acquisition cost for the treatment will be $3.5 million, making it...